Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in
contrast to the general population with basal and squamous cell skin cancer. The use of
immunosuppressant or anti-rejection drugs that are needed after SOTR is known to increase the
risk of developing certain kinds of cancer. The purpose of this study is to find out how well
Sirolimus (also known as Rapamune) works at treating squamous cell carcinoma in renal
transplant patients.